ACC In Brief
This article was originally published in The Tan Sheet
Executive Summary
PREVU(x) POC in action: A skin sterol testing method was successfully employed to detect subclinical vascular disease, according to an 81-subject study presented by Wendy Tzou, MD, University of Wisconsin Medical School, et al., at the American College of Cardiology Annual Scientific Session in Orlando, Fla. March 7. Carotid intima media thickness, "a well-established marker of atherosclerosis," was significantly higher among patients in the population exhibiting the highest skin sterol measurement using PREVU(x) Point of Care test, according to the test's marketer, Toronto-based IMI. The data "confirm that skin sterol testing has the ability to help identify patients at risk of heart disease non-invasively and cost effectively," CEO Brent Norton asserts. IMI signed a marketing agreement with McNeil last year and is developing an OTC version of the product (1"The Tan Sheet" June 7, 2004, p. 10)...